• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Tolerogenic vaccines for Multiple Sclerosis

    Thumbnail
    View/ Open
    hvi-9-1032.PMC3899137.pdf (454.2Kb)

    Show full item record
    
    Author
    Mannie, Mark D.; Curtis II, Alan Dale
    Abstract
    Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.
    URI
    http://hdl.handle.net/10342/5655
    Subject
     autoimmune disease; experimental autoimmune encephalomyelitis; immune; multiple sclerosis; myelin; neuroantigen; T lymphocytes; therapy; tolerance; vaccine 
    Date
    2013-05
    Citation:
    APA:
    Mannie, Mark D., & Curtis II, Alan Dale. (May 2013). Tolerogenic vaccines for Multiple Sclerosis. Human Vaccines & Immunotherapeutics, (9:5), p.1032-1038. Retrieved from http://hdl.handle.net/10342/5655

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Mannie, Mark D., and Curtis II, Alan Dale. "Tolerogenic vaccines for Multiple Sclerosis". Human Vaccines & Immunotherapeutics. 9:5. (1032-1038.), May 2013. April 18, 2021. http://hdl.handle.net/10342/5655.
    Chicago:
    Mannie, Mark D. and Curtis II, Alan Dale, "Tolerogenic vaccines for Multiple Sclerosis," Human Vaccines & Immunotherapeutics 9, no. 5 (May 2013), http://hdl.handle.net/10342/5655 (accessed April 18, 2021).
    AMA:
    Mannie, Mark D., Curtis II, Alan Dale. Tolerogenic vaccines for Multiple Sclerosis. Human Vaccines & Immunotherapeutics. May 2013; 9(5) 1032-1038. http://hdl.handle.net/10342/5655. Accessed April 18, 2021.
    Collections
    • Microbiology and Immunology

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback